Biolyst › BLRXBioLineRx Ltd. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
No upcoming catalysts are currently on record for BLRX. Past events are listed below.
Cash runway is approximately 7 months based on the most recent reported cash position and quarterly operating burn as of 2025-12-31.
Across 16 concluded trials, 75% reached completion rather than being terminated or withdrawn.
Upcoming catalysts
Nothing scheduled.
Track BLRX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open BLRX in the tracker
Recent history
Date Event Type Phase
September 24, 2026
6-K filed: Foreign issuer report Filing
—
September 10, 2026
6-K filed: Foreign issuer report Filing
—
August 31, 2026
6-K filed: Foreign issuer report Filing
—
August 31, 2026
6-K filed: Foreign issuer report Filing
—
August 28, 2026
6-K filed: Foreign issuer report Filing
—
August 18, 2026
6-K filed: Foreign issuer report Filing
—
July 8, 2026
6-K filed: Foreign issuer report Filing
—
May 27, 2026
6-K filed: Foreign issuer report Filing
—
May 22, 2026
6-K filed: Foreign issuer report Filing
—
May 19, 2026
6-K filed: Foreign issuer report Filing
—
April 28, 2026
6-K filed: Foreign issuer report Filing
—
March 27, 2026
Results filed (20-F/A) Earnings
—
March 26, 2026
6-K filed: Foreign issuer report Filing
—
March 23, 2026
Results filed (20-F) Earnings
—
March 23, 2026
6-K filed: Foreign issuer report Filing
—
February 23, 2026
6-K filed: Foreign issuer report Filing
—
November 24, 2025
6-K filed: Foreign issuer report Filing
—
November 17, 2025
6-K filed: Foreign issuer report Filing
—
September 29, 2025
6-K filed: Foreign issuer report Filing
—
August 14, 2025
6-K filed: Foreign issuer report Filing
—
June 30, 2025
6-K filed: Foreign issuer report Filing
—
May 30, 2025
6-K filed: Foreign issuer report Filing
—
May 27, 2025
6-K filed: Foreign issuer report Filing
—
May 23, 2025
6-K filed: Foreign issuer report Filing
—
September 6, 2022
Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients Trial Milestone
Phase 2
June 1, 2022
Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy Subjects Trial Milestone
Phase 1
December 22, 2020
A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM) Trial Milestone
Phase 3
November 15, 2020
Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome Trial Milestone
Phase 2
April 1, 2020
Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML) Trial Milestone
Phase 1/Phase 2
About this data
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.